Difference between revisions of "Real World Evidence"

From PHUSE Wiki
Jump to: navigation, search
m (Project Members)
m (Project Leads)
(2 intermediate revisions by the same user not shown)
Line 17: Line 17:
 
|Andy Richardson || Co-Lead || Independent|| andy.richardson@phuse.eu
 
|Andy Richardson || Co-Lead || Independent|| andy.richardson@phuse.eu
 
|-
 
|-
 
+
|David Hood || Co-Lead || Pfizer || david.hood@pfizer.com
 
+
|-
 +
|Sangeeta Bhattacharya || Co-Lead || JNJ || sbhatt11@its.jnj.com
 +
|-
 
|}
 
|}
  
Line 39: Line 41:
 
|-
 
|-
 
|Corey Young || EdjAnalytics  
 
|Corey Young || EdjAnalytics  
|-
 
|David Hood ||Pfizer
 
 
|-
 
|-
 
|Marcus Lawrance || Roche
 
|Marcus Lawrance || Roche
Line 53: Line 53:
 
|-
 
|-
 
|Rosa Bianca Gallo || The Hyve
 
|Rosa Bianca Gallo || The Hyve
|-
 
|Sangeeta Bhattacharya || JNJ
 
 
|-
 
|-
 
|Scott Bahlavooni || Industry  
 
|Scott Bahlavooni || Industry  

Revision as of 06:27, 12 July 2019


Project Overview


The increasing interest/pressure to including results based on real world data as part of regulated clinical trial submissions and similar research initiatives is testing how current regulatory and good practice requirements can incorporate these results into submissions. Whilst specific projects have successfully addressed these issues, RWE guidelines or points for consideration are not yet formalised. PhUSE members are centrally involved in the management and analysis of these data, and best practice guidance for dealing with RWE data would assist members in this space. The project has three goals: 1: Establish a PhUSE project or WG to focus on RWE issues. 2: Develop a white paper / presentation focused on establishing the range of areas that need to be considered/impact on the use of RWE in support of regulated clinical trial submissions. This would be focused on identifying issues such as data sources, RWE technologies, data privacy and related issues, standards etc. impacting on RWE use. (e.g. see PhUSE SDE London May 2019 presentations). 3: Identify and prioritise future RWE projects/sub-projects.

Project Leads

Name Role Organization E-mail
Andy Richardson Co-Lead Independent andy.richardson@phuse.eu
David Hood Co-Lead Pfizer david.hood@pfizer.com
Sangeeta Bhattacharya Co-Lead JNJ sbhatt11@its.jnj.com

Project Members

Name Organisation
Adam Reich IQVIA
Andy Steen EdjAnalytics.com
Anil Sekhari Sekharico Informatics
Berber Snoeijer Clinline
Charan Kumar Ephicacy
Corey Young EdjAnalytics
Marcus Lawrance Roche
Nurcan Coskun Industry
Oluseun Shittu GlaxoSmithKline
Paul Murray SAS
Rachel Bowman Loxley Analytics
Rosa Bianca Gallo The Hyve
Scott Bahlavooni Industry
Shelley Fordred GSK
Siddharth Arthi Zifornd
Susan Olson EdjAnalytics
Trisha Simpson UCB
Yixun Wu Syneoshealth

Project Activities


Project Updates


Objectives and Timelines

List proposed project deliverables and timelines.

Objective Timeline
Establish PhUSE RWE Project / WG Sep-2019
PhUSE Whitepaper/Presentation: Basic Considerations for the Use of RWE Data in Support of Regulated Clinical Trial Submissions Dec-2019
Consider and initiate RWE projects/sub-projects in identified areas for future consideration Dec-2019